Quick Answer
TherapeuticsMD, Inc. reported Diluted EPS of $0.05 per share (loss) for fiscal year 2025.
TherapeuticsMD, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.05 | +73.7% |
| 2024 | -$0.19 | +80.8% |
| 2023 | -$0.99 | -108.3% |
| 2022 | $11.96 | +155.2% |
| 2021 | -$21.66 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.01 | +120.0% | -80.0% |
| June 30, 2025 | $0.05 | +155.6% | +183.3% |
| March 31, 2025 | -$0.06 | +0.0% | -20.0% |
| September 30, 2024 | -$0.05 | +84.4% | +44.4% |
| June 30, 2024 | -$0.09 | +62.5% | -50.0% |
| March 31, 2024 | -$0.06 | +83.8% | +81.2% |
| September 30, 2023 | -$0.32 | +89.8% | -33.3% |
| June 30, 2023 | -$0.24 | -101.9% | +35.1% |
- TherapeuticsMD, Inc. showed an increase of +73.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, TherapeuticsMD, Inc.’s diluted eps has grown by 99.8% (from $21.66 per share (loss) to $0.05 per share (loss)).
- The most recent figure is from TherapeuticsMD, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: